JP2017132791A - 組み合わせ組成物 - Google Patents
組み合わせ組成物 Download PDFInfo
- Publication number
- JP2017132791A JP2017132791A JP2017055893A JP2017055893A JP2017132791A JP 2017132791 A JP2017132791 A JP 2017132791A JP 2017055893 A JP2017055893 A JP 2017055893A JP 2017055893 A JP2017055893 A JP 2017055893A JP 2017132791 A JP2017132791 A JP 2017132791A
- Authority
- JP
- Japan
- Prior art keywords
- ibuprofen
- paracetamol
- combination
- composition
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
【解決手段】該組成物はイブプロフェンとパラセタモールの組み合わせを人に投与するために:a)約125〜約175mgのイブプロフェンと約475〜約525mgのパラセタモールとの組み合わせ、或いは、b)約275〜約325mgのイブプロフェンと約975〜約1,025mgのパラセタモールとの組み合わせ;のような投与量で有する静脈投与組成物。前記投与量を、約6時間毎に投与することが好ましい、静脈投与組成物。
【選択図】なし
Description
a)約125mg乃至約175mgのイブプロフェンと約475mg乃至約525mgのパラセタモールとの組み合わせ;あるいは
b)約275mg乃至約325mgのイブプロフェンと約975mg乃至約1,025mgのパラセタモールとの組み合わせ。
a)約150mgのイブプロフェンと約500mgのパラセタモールとの組み合わせ;あるいは
b)約300mgのイブプロフェンと約1,000mgのパラセタモールとの組み合わせ;
を含む。
a)約125mg乃至約175mgのイブプロフェンと約475mg乃至約525mgのパラセタモールとの組み合わせ;あるいは
b)約275mg乃至約325mgのイブプロフェンと約975mg乃至約1,025mgのパラセタモールとの組み合わせ;
を含む。
a)約150mgのイブプロフェンと約500mgのパラセタモールとの組み合わせ;あるいは
b)約300mgのイブプロフェンと約1,000mgのパラセタモールとの組み合わせ;
を含む。
a)約125mg乃至約175mgのイブプロフェンと約475mg乃至約525mgのパラセタモールとの組み合わせ;あるいは
b)約275mg乃至約325mgのイブプロフェンと約975mg乃至約1,025mgのパラセタモールとの組み合わせ;
を含む薬剤を、静脈から人に投与することで痛み及び/又は炎症を治療する方法を含む。
a)約150mgのイブプロフェンと約500mgのパラセタモールとの組み合わせ;あるいは
b)約300mgのイブプロフェンと約1,000mgのパラセタモールとの組み合わせ;
を含む。
Claims (8)
- 痛み及び/又は炎症を鎮めるための静脈投与組成物であって、該組成物が、人に投与するイブプロフェンとパラセタモールの組み合わせを:
a)約125mg乃至約175mgのイブプロフェンと約475mg乃至約525mgのパラセタモールとの組み合わせ;あるいは
b)約275mg乃至約325mgのイブプロフェンと約975mg乃至約1,025mgのパラセタモールとの組み合わせ;
で有することを特徴とする組成物。 - 約6時間毎に投与されることを特徴とする、請求項1に記載の静脈投与組成物。
- a)約150mgのイブプロフェンと約500mgのパラセタモールとの組み合わせ;あるいは
b)約300mgのイブプロフェンと約1,000mgのパラセタモールとの組み合わせ;
を含むことを特徴とする請求項1又は2に記載の静脈投与組成物。 - 液剤であることを特徴とする、請求項1、2又は3に記載の静脈投与組成物。
- 人の痛み及び/又は炎症の治療用静脈内薬剤の製造におけるパラセタモールとイブプロフェンの使用であって、該薬剤が一回の投与量あたり:
a)約125mg乃至約175mgのイブプロフェンと約475mg乃至約525mgのパラセタモールとの組み合わせ;あるいは
b)約275mg乃至約325mgのイブプロフェンと約975mg乃至約1,025mgのパラセタモールとの組み合わせ;
を含むことを特徴とする使用。 - この使用において、該薬剤組成物は、約6時間おきに投与される、請求項5に記載の使用。
- 該薬剤組成物が:
a)約150mgのイブプロフェンと約500mgのパラセタモールとの組み合わせ;あるいは
b)約300mgのイブプロフェンと約1,000mgのパラセタモールとの組み合わせ;
を含むことを特徴とする請求項5又は6に記載の使用。 - 該薬剤組成物が液剤であることを特徴とする、請求項5、6又は7に記載の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ589011 | 2010-11-04 | ||
NZ58901110 | 2010-11-04 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013537631A Division JP2013541583A (ja) | 2010-11-04 | 2011-10-26 | 組み合わせ組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017132791A true JP2017132791A (ja) | 2017-08-03 |
JP6353577B2 JP6353577B2 (ja) | 2018-07-04 |
Family
ID=46024668
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013537631A Pending JP2013541583A (ja) | 2010-11-04 | 2011-10-26 | 組み合わせ組成物 |
JP2017055893A Active JP6353577B2 (ja) | 2010-11-04 | 2017-03-22 | 組み合わせ組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013537631A Pending JP2013541583A (ja) | 2010-11-04 | 2011-10-26 | 組み合わせ組成物 |
Country Status (27)
Country | Link |
---|---|
US (4) | US20130225685A1 (ja) |
EP (1) | EP2635269B1 (ja) |
JP (2) | JP2013541583A (ja) |
KR (1) | KR101900520B1 (ja) |
CN (2) | CN107519159A (ja) |
AU (1) | AU2011324137B2 (ja) |
BR (1) | BR112013010829B1 (ja) |
CA (1) | CA2814057C (ja) |
CL (1) | CL2013001250A1 (ja) |
CO (1) | CO6771406A2 (ja) |
CY (1) | CY1123398T1 (ja) |
DK (1) | DK2635269T3 (ja) |
ES (1) | ES2742373T3 (ja) |
HR (1) | HRP20191489T1 (ja) |
HU (1) | HUE045442T2 (ja) |
LT (1) | LT2635269T (ja) |
MX (2) | MX2013005113A (ja) |
MY (1) | MY160572A (ja) |
NZ (1) | NZ609727A (ja) |
PH (1) | PH12021550804A1 (ja) |
PL (1) | PL2635269T3 (ja) |
PT (1) | PT2635269T (ja) |
RS (1) | RS59258B1 (ja) |
RU (2) | RU2013123646A (ja) |
SG (1) | SG189319A1 (ja) |
SI (1) | SI2635269T1 (ja) |
WO (1) | WO2012060719A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2635269T3 (pl) | 2010-11-04 | 2019-11-29 | Aft Pharmaceuticals Ltd | Kompozycja złożona |
US9072710B2 (en) | 2012-03-16 | 2015-07-07 | Cumberland Pharmaceuticals Inc. | Injectable ibuprofen formulation |
WO2016008546A1 (en) * | 2014-07-18 | 2016-01-21 | Everbright Pharmaceuticals S.A.R.L. | Aqueous formulation comprising paracetamol and ibuprofen |
CA2963916A1 (en) * | 2014-10-06 | 2016-04-14 | Cumberland Pharmaceuticals, Inc. | Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain |
WO2018192664A1 (en) | 2017-04-20 | 2018-10-25 | Hyloris Developments Sa | METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF |
KR102642847B1 (ko) * | 2017-07-10 | 2024-03-04 | 젤 캡 테크놀로지스 엘엘씨 | 이중 방출 투여형 캡슐 및 이를 제조하기 위한 방법, 장치 및 시스템 |
US11197830B2 (en) | 2019-02-27 | 2021-12-14 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetaminophen and ibuprofen |
US11568752B2 (en) * | 2020-01-28 | 2023-01-31 | David Clark Company Incorporated | Gateway retrieval alert device for aircraft pushback operations |
WO2023281089A2 (en) | 2021-07-08 | 2023-01-12 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising naproxen and paracetamol |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005510510A (ja) * | 2001-11-02 | 2005-04-21 | カンバーランド ファーマシューティカルズ,インコーポレーテッド | 2−(4−イソブチルフェニル)プロピオン酸の医薬組成物 |
KR20060072839A (ko) * | 2004-12-23 | 2006-06-28 | 김경태 | 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020551A1 (en) * | 1995-12-05 | 1997-06-12 | Adcock Ingram Limited | Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic |
CA2519772C (en) * | 2003-03-21 | 2016-05-31 | Mcneil-Ppc, Inc. | Use of acetaminophen for providing a sustained therapeutic effect |
BRPI0512756A (pt) * | 2004-07-07 | 2008-04-08 | Aft Pharmaceuticals Ltd | composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas |
US7934627B2 (en) * | 2005-10-13 | 2011-05-03 | Alcoa Inc. | Apparatus and method for high pressure extrusion with molten aluminum |
JP5389656B2 (ja) * | 2006-10-20 | 2014-01-15 | マクニール−ピーピーシー・インコーポレーテツド | アセトアミノフェン/イブプロフェンの組み合わせおよびこれらの使用方法 |
WO2008079818A2 (en) * | 2006-12-21 | 2008-07-03 | Soluprin Pharmaceuticals, Inc. | Intravenous administration of water soluble analgesic formulations |
US20090264530A1 (en) * | 2008-04-16 | 2009-10-22 | Nickell Robert P | Combined nsaid and acetaminophen formulation and method |
BRPI0914086A2 (pt) * | 2008-10-14 | 2020-01-21 | Aft Pharmaceuticals Ltd | uso de paracetamol e ibuprofeno na preparação de um medicamento para o tratamento de osteoartrite moderada ou severa ou artrite reumatoide moderada ou severa e método de tratamento de osteoartrite moderada ou severa ou artrite reumatoide moderada ou severa |
ES2823249T3 (es) * | 2009-03-12 | 2021-05-06 | Cumberland Pharmaceuticals Inc | Administración de ibuprofeno por vía intravenosa |
WO2012005605A1 (en) * | 2010-07-07 | 2012-01-12 | Aft Pharmaceuticals Limited | A combination composition comprising ibuprofen and paracetamol |
PL2635269T3 (pl) | 2010-11-04 | 2019-11-29 | Aft Pharmaceuticals Ltd | Kompozycja złożona |
CA2963916A1 (en) * | 2014-10-06 | 2016-04-14 | Cumberland Pharmaceuticals, Inc. | Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain |
-
2011
- 2011-10-26 PL PL11838295T patent/PL2635269T3/pl unknown
- 2011-10-26 ES ES11838295T patent/ES2742373T3/es active Active
- 2011-10-26 WO PCT/NZ2011/000226 patent/WO2012060719A1/en active Application Filing
- 2011-10-26 CN CN201710623266.5A patent/CN107519159A/zh active Pending
- 2011-10-26 CN CN2011800525659A patent/CN103298464A/zh active Pending
- 2011-10-26 RU RU2013123646/15A patent/RU2013123646A/ru not_active Application Discontinuation
- 2011-10-26 AU AU2011324137A patent/AU2011324137B2/en active Active
- 2011-10-26 LT LTEP11838295.1T patent/LT2635269T/lt unknown
- 2011-10-26 PT PT11838295T patent/PT2635269T/pt unknown
- 2011-10-26 HU HUE11838295A patent/HUE045442T2/hu unknown
- 2011-10-26 DK DK11838295.1T patent/DK2635269T3/da active
- 2011-10-26 RS RSP20190963 patent/RS59258B1/sr unknown
- 2011-10-26 KR KR1020137014178A patent/KR101900520B1/ko active IP Right Review Request
- 2011-10-26 JP JP2013537631A patent/JP2013541583A/ja active Pending
- 2011-10-26 CA CA2814057A patent/CA2814057C/en active Active
- 2011-10-26 SG SG2013026265A patent/SG189319A1/en unknown
- 2011-10-26 SI SI201131767T patent/SI2635269T1/sl unknown
- 2011-10-26 MX MX2013005113A patent/MX2013005113A/es not_active Application Discontinuation
- 2011-10-26 BR BR112013010829-0A patent/BR112013010829B1/pt active IP Right Grant
- 2011-10-26 MY MYPI2013001237A patent/MY160572A/en unknown
- 2011-10-26 MX MX2015008709A patent/MX367209B/es unknown
- 2011-10-26 RU RU2015103107A patent/RU2707089C2/ru active
- 2011-10-26 NZ NZ609727A patent/NZ609727A/en unknown
- 2011-10-26 EP EP11838295.1A patent/EP2635269B1/en active Active
- 2011-10-26 US US13/882,953 patent/US20130225685A1/en not_active Abandoned
-
2013
- 2013-05-06 CL CL2013001250A patent/CL2013001250A1/es unknown
- 2013-05-22 CO CO13125952A patent/CO6771406A2/es not_active Application Discontinuation
-
2015
- 2015-08-21 US US14/832,154 patent/US20160235695A1/en not_active Abandoned
-
2017
- 2017-03-22 JP JP2017055893A patent/JP6353577B2/ja active Active
-
2018
- 2018-10-01 US US16/149,109 patent/US11446266B2/en active Active
-
2019
- 2019-07-18 CY CY20191100766T patent/CY1123398T1/el unknown
- 2019-08-16 HR HRP20191489 patent/HRP20191489T1/hr unknown
-
2021
- 2021-04-08 PH PH12021550804A patent/PH12021550804A1/en unknown
-
2022
- 2022-09-13 US US17/943,708 patent/US11896567B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005510510A (ja) * | 2001-11-02 | 2005-04-21 | カンバーランド ファーマシューティカルズ,インコーポレーテッド | 2−(4−イソブチルフェニル)プロピオン酸の医薬組成物 |
KR20060072839A (ko) * | 2004-12-23 | 2006-06-28 | 김경태 | 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6353577B2 (ja) | 組み合わせ組成物 | |
JP6381761B2 (ja) | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 | |
JP7042531B2 (ja) | デオキシコール酸を含む医薬組成物 | |
RU2552345C2 (ru) | Лекарственная форма для чресслизистого перорального введения анальгетических и/или антиспазматических молекул | |
KR20150050595A (ko) | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 | |
KR20200055067A (ko) | 성인의 초점성 뇌전증의 치료를 위한 합성 경피성 칸나비디올 | |
KR20170066549A (ko) | 통증 치료를 위한 이부프로펜과 아세트아미노펜의 공동 정맥 투여 | |
JP2012505830A (ja) | 医薬品及び医薬品治療 | |
AU2011274652B2 (en) | A combination composition comprising ibuprofen and paracetamol | |
JP5435659B2 (ja) | トリプタンの経口腔粘膜投与用製剤形態 | |
ES2668943T3 (es) | Composición farmacéutica para tratar eyaculación precoz y método de tratamiento de la eyaculación precoz | |
KR20120089444A (ko) | 정맥내 이부프로펜에 의한 위독한 환자의 치료방법 | |
JP2019001830A (ja) | 医薬 | |
JP5607408B2 (ja) | アレンドロン酸含有注射剤 | |
CN117243948A (zh) | 包含瑞香素的组合物在制备风湿性关节炎药物中的应用 | |
TW200838534A (en) | Treatment for irritable bowel syndrome | |
WO2011000563A4 (en) | Eltoprazine for the treatment of weight disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180316 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180605 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180522 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180608 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6353577 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |